AbbVie stock holds firm as Humira biosimilar impact is offset by Skyrizi and Rinvoq growth

AbbVie stock, tied to the performance of the US biopharmaceutical group AbbVie Inc. (ISIN US00287Y1091) listed on the New York Stock Exchange, has been supported by a changing mix of immunology revenues as the company manages the loss of exclusivity on Humira with strong uptake of its newer therapies Skyrizi and Rinvoq. As of 30 April 2024, AbbVie reported that combined Skyrizi and Rinvoq revenues reached several billion US dollars on an annualized basis, growing sharply year over year and increasingly offsetting the decline in Humira sales according to the company’s investor materials on its corporate website.

Immunology revenue shifts after Humira loss of exclusivity

According to AbbVie’s published financial information for full-year 2023 on its official site AbbVie investors section, total net revenues across all segments reached tens of billions of US dollars in 2023, with immunology remaining the largest contributor despite the impact of US biosimilar competition to Humira. In that period, global sales of Humira declined compared with 2022 as biosimilar rivals entered the US market following loss of exclusivity, while newer products Skyrizi (risankizumab) and Rinvoq (upadacitinib) delivered strong year-over-year growth and together generated several billion US dollars of revenue in 2023.

The company’s disclosures for early 2024 highlight that Skyrizi and Rinvoq have become central growth drivers in immunology. AbbVie indicated that in 2023 Skyrizi achieved a substantial double-digit percentage revenue increase compared with 2022, while Rinvoq also posted significant double-digit revenue growth versus the prior year. These gains helped to reduce AbbVie’s reliance on Humira and provided investors with visibility on how the product portfolio is shifting toward newer treatments with longer remaining patent lives.

Revenue mix, margins and cash flow matter for AbbVie stock

AbbVie’s investor presentations describe how the revenue mix influences margins and cash flow. In 2023, the company reported operating earnings and adjusted earnings per share that reflected both the erosion of high-margin Humira revenues and the ramp-up of newer products. According to AbbVie’s financial overview on its website AbbVie financials, adjusted diluted earnings per share for 2023 were several US dollars, representing a decline compared with 2022 as expected from the Humira cliff but still underpinned by strong business fundamentals.

The company has emphasized its capacity to generate robust operating cash flow. In 2023, AbbVie’s cash flow from operations amounted to many billions of US dollars, providing flexibility to sustain its dividend, invest in research and development, and pursue strategic deals. The dividend itself remains an important metric for AbbVie stock: AbbVie communicated an annualized dividend rate in the range of several US dollars per share, translating into an attractive yield based on its share price over 2023 and early 2024. For investors, the stability of this cash return is a key consideration when assessing the resilience of AbbVie’s equity story in the face of the Humira transition.

Skyrizi and Rinvoq expand AbbVie’s immunology franchise

Skyrizi is a monoclonal antibody targeting interleukin 23, and AbbVie has positioned it as a key therapy for plaque psoriasis, psoriatic arthritis and Crohn’s disease. In its product overview, AbbVie states that Skyrizi reached several billion US dollars in sales in 2023, climbing strongly from 2022 as more indications and geographies were added. The company has highlighted Skyrizi’s performance as central to its long-term growth algorithm.

Rinvoq, a Janus kinase (JAK) inhibitor, complements Skyrizi in AbbVie’s immunology franchise. Rinvoq posted revenue of multiple billions of US dollars in 2023, according to AbbVie’s product revenue disclosures, and has gained approval in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and other immune-mediated diseases. These two drugs together form a pillar of AbbVie’s strategy to partially replace the revenue lost from Humira while addressing unmet medical needs in inflammatory conditions.

Dividend, debt and capital allocation underpin investor appeal

AbbVie regularly communicates its capital allocation priorities, which include maintaining an attractive dividend, reducing debt incurred from past acquisitions, and investing in internal and external innovation. The company’s investor information indicates that AbbVie has paid dividends totaling several dollars per share annually in recent years, with a track record of annual increases since it was spun off from Abbott Laboratories in 2013.

On the balance sheet side, AbbVie carries a substantial level of long-term debt as a result of transactions such as the acquisition of Allergan. In its financial tables for year-end 2023, AbbVie reports long-term debt in the tens of billions of US dollars. Management has stated that deleveraging remains a priority, supported by strong cash generation, and investors monitor both net leverage ratios and interest expense closely when assessing AbbVie stock’s risk profile.

Pipeline and oncology portfolio contribute to long-term narrative

Beyond immunology, AbbVie’s portfolio includes products in oncology, neuroscience and other therapeutic areas. The oncology franchise features Imbruvica, Venclexta and other agents used in hematological malignancies. While some of these products face competitive pressures, they also provide diversification away from immunology and create additional avenues for growth.

AbbVie’s pipeline includes numerous phase 2 and phase 3 programs, according to summaries on the company’s research and development pages. These span indications such as dermatology, gastroenterology, rheumatology, oncology and neurology. For retail investors, the pipeline’s breadth is relevant because successful late-stage trials can translate into future regulatory approvals and revenues, while setbacks may affect sentiment and valuation.

Product focus: Skyrizi in plaque psoriasis and Crohn’s disease

Skyrizi is a representative product for AbbVie’s current growth story. Initially approved for moderate to severe plaque psoriasis, Skyrizi has since gained approval in psoriasis-related arthritis and Crohn’s disease in several regions. This expansion has helped drive the strong revenue increases reported for the drug in 2023 compared with 2022, according to AbbVie’s product revenue breakdown.

For patients with chronic inflammatory conditions, Skyrizi offers targeted inhibition of interleukin 23 and is administered as an injection with dosing intervals that can be more convenient than some older biologic therapies. From an investor perspective, Skyrizi’s growing label and increasing physician adoption support the thesis that AbbVie can build a durable portfolio of next-generation immunology drugs.

AbbVie stock and market valuation context

AbbVie stock trades on the New York Stock Exchange under the ticker ABBV. Over 2023 and early 2024, AbbVie’s share price reflected both the anticipated Humira revenue erosion and confidence in the newer portfolio. At various points in 2023, the equity’s market capitalization stood in the range of tens of billions of US dollars, placing AbbVie among the larger constituents of the S&P 500 index.

For retail investors analyzing AbbVie stock, the key metrics include revenue trends in immunology, progress in the pipeline, margin development, and the sustainability of the dividend relative to cash flow and leverage. The company’s strategy of using Skyrizi and Rinvoq to offset the Humira cliff is central to its medium-term outlook, while diversification into areas such as oncology and neuroscience provides additional opportunities and risks.